Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $37.0 million.

  • Altimmune's Cash & Equivalents rose 94.43% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 94.43%. This contributed to the annual value of $37.0 million for FY2024, which is 72.65% down from last year.
  • As of FY2024, Altimmune's Cash & Equivalents stood at $37.0 million, which was down 72.65% from $135.2 million recorded in FY2023.
  • In the past 5 years, Altimmune's Cash & Equivalents registered a high of $190.3 million during FY2021, and its lowest value of $37.0 million during FY2024.
  • In the last 3 years, Altimmune's Cash & Equivalents had a median value of $111.1 million in 2022 and averaged $94.4 million.
  • In the last 5 years, Altimmune's Cash & Equivalents skyrocketed by 1,188.81% in 2020 and then slumped by 72.65% in 2024.
  • Over the past 5 years, Altimmune's Cash & Equivalents (Yearly) stood at $116.0 million in 2020, then skyrocketed by 64.15% to $190.3 million in 2021, then crashed by 41.61% to $111.1 million in 2022, then climbed by 21.62% to $135.2 million in 2023, then tumbled by 72.65% to $37.0 million in 2024.